Tag Archives: Liso-cel

Thoughts on the EMA Validating BMS’s Liso-cel Marketing Authorization Application

On Friday, July 17, BMS announced (press release) that the EMA has validated BMS’s MAA for lisocabtagene maraleucel (liso-cel). Below, Celltelligence provides thoughts on Liso-cel’s MAA and the potential impact of a Liso-cel approval for Novartis and Gilead (Kite).

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.